Cerus Corp
NASDAQ:CERS

Watchlist Manager
Cerus Corp Logo
Cerus Corp
NASDAQ:CERS
Watchlist
Price: 1.63 USD -0.61%
Market Cap: 302.7m USD
Have any thoughts about
Cerus Corp?
Write Note

Cerus Corp
Intangible Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cerus Corp
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
Cerus Corp
NASDAQ:CERS
Intangible Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Haemonetics Corp
NYSE:HAE
Intangible Assets
$487.8m
CAGR 3-Years
13%
CAGR 5-Years
34%
CAGR 10-Years
7%
ICU Medical Inc
NASDAQ:ICUI
Intangible Assets
$785.8m
CAGR 3-Years
60%
CAGR 5-Years
43%
CAGR 10-Years
59%
Align Technology Inc
NASDAQ:ALGN
Intangible Assets
$115.9m
CAGR 3-Years
0%
CAGR 5-Years
54%
CAGR 10-Years
18%
Lantheus Holdings Inc
NASDAQ:LNTH
Intangible Assets
$173.6m
CAGR 3-Years
-21%
CAGR 5-Years
86%
CAGR 10-Years
19%
Merit Medical Systems Inc
NASDAQ:MMSI
Intangible Assets
$372.2m
CAGR 3-Years
4%
CAGR 5-Years
-4%
CAGR 10-Years
13%
No Stocks Found

Cerus Corp
Glance View

Market Cap
302.6m USD
Industry
Health Care

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 294 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

CERS Intrinsic Value
1.41 USD
Overvaluation 14%
Intrinsic Value
Price

See Also

Back to Top